CureVac N.V. (CVAC)
Fuera de horario:
CureVac N.V.
Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Alexander Zehnder M.B.A., M.D. | CEO, MD & Member of Management Board | 1.05M | N/D | 1970 |
| Mr. Pierre Kemula B.Sc. | MD, CFO & Member of Management Board | 699.9k | N/D | 1975 |
| Dr. Malte Greune Ph.D. | COO, Member of Management Board & MD | 642.73k | N/D | 1965 |
| Dr. Myriam Mendila M.D. | Chief Development Officer, MD & Member of the Management Board | 657.44k | N/D | 1966 |
| Dr. Ulrike Gnad-Vogt M.D., Ph.D. | Senior VP & Area Head of Oncology | 304.01k | N/D | 1973 |
| Dr. Sarah Fakih | Vice President Corporate Communications & Investor Relations | N/D | N/D | N/D |
| Mr. Marco Rau L.L.M., Ph.D. | General Counsel | N/D | N/D | N/D |
| Mr. Thorsten Schuller | Head of Corporate Communications | N/D | N/D | N/D |
| Slavica Stevanovic-Heck | Head of Human Resources | N/D | N/D | N/D |
| Dr. Patrick Baumhof | Senior Vice President of Technology | N/D | N/D | N/D |
Descripción
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Gestión corporativa
La calificación ISS Governance QuickScore de CureVac N.V. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
